2.55
0.07 (2.82%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Chemomab Therapeutics Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 0.17 |
|
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 15.27% |
| % Held by Institutions | 16.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Adar1 Capital Management, Llc | 30 Jun 2026 | 80,000 |
| Kestra Private Wealth Services, Llc | 30 Jun 2026 | 61,710 |
| Ikarian Capital, Llc | 30 Jun 2026 | 51,793 |
| Rhumbline Advisers | 30 Jun 2026 | 30,529 |
| Philadelphia Investment Partners, Llc | 30 Jun 2026 | 15,000 |
| Lido Advisors, Llc | 30 Jun 2026 | 14,341 |
| Gamma Investing Llc | 30 Jun 2026 | 4,740 |
| Smartharvest Portfolios, Llc | 30 Jun 2026 | 0 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |